INTRODUCTION
In recent years, particular attention has been paid to anal cancer because of its increasing incidence in men who have sex with men (MSM) and human immunodeficiency virus (HIV)-infected individuals. [1] [2] [3] [4] [5] In the latter population, anal cancer represents one of the most common non-AIDS defining malignancies. 6 Nonetheless, consensus guidelines for anal cancer screening are lacking, and the target populations as well as the most effective tools in preventing such neoplasias have yet to be identified. 7 A lack of comprehensive data concerning the natural history of anal cancer and the possibility of preventing this cancer through the identification and treatment of highgrade anal intraepithelial neoplasia (HGAIN) mostly hampers the development of specific guidelines. Despite these facts, several hospital-level experiences in anal cancer screening are being increasingly reported. [8] [9] [10] [11] [12] [13] They mostly rely on a digital anorectal examination to detect early-stage cancer or anal cytology in combination with other diagnostic procedures when abnormal results are found. Even though high-resolution anoscopy (HRA)-guided biopsies currently represent the gold standard for the identification of HGAIN, 14 HRA is a complex procedure and is not available at most clinical centers. Even though the implementation of anal cancer screening is increasingly advocated, very limited experiences in this regard have been reported in Europe. European studies of anal cytology have been conducted only in small to medium cohorts. In Italy, only a few centers routinely use anal cytology to screen populations at increased risk for anal cancer, 15, 16 even though Italian guidelines for the care and management of HIV-infected individuals recommend an annual anal Papanicolaou (Pap) test followed by HRA when abnormalities are detected. 17 This cross-sectional study assessed the prevalence of anal cytological lesions and anal human papillomavirus (HPV) infections in a large group of HIV-infected and HIV-uninfected MSM attending a center for sexually transmitted infections (STIs) and HIV, where liquid-based anal cytology has been used since 2009. 18 We also estimated the frequency of cytological lesions according to age class and evaluated possible associations of cytological abnormalities at different thresholds with HPV infection. Finally, possible determinants of abnormal cytological findings among viro-immunological parameters were analyzed for the HIV-infected individuals. 
MATERIALS AND METHODS

Study Population
HPV-DNA Testing
The Linear Array HPV genotyping test (Roche Diagnostics) was used to assess the presence of HPV DNA, as previously described. 21, 22 
Data Analysis
The sample size calculation was performed under the assumption of prevalences of cytological abnormalities of 25% (HIV-uninfected) and 47% (HIV-infected), as reported by D'Souza et al, 23 and a maximum standard error of 5%. Descriptive statistics were used to summarize the characteristics of the 2 study groups for the variables of interest. As for the CD4 1 T-cell count and the HIV load, the measurements closest to the anal sampling were considered for the analysis. The odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated. A P value < .05 was considered statistically significant. Statistical analyses were performed with SPSS 21 software (SPSS, Inc, Chicago, Illinois).
RESULTS
Study Population
During the study period, 1021 MSM were enrolled: 633 (62.0%) were HIV-uninfected, and 388 (38.0%) were HIV-infected. For 48 HIV-positive MSM who attended our center from other urban HIV facilities only to undergo the anal Pap test, viro-immunological parameters were unknown. The remaining 340 patients had median nadir and current CD4 ), respectively; 89.7% of these patients were on combined antiretroviral therapy (cART). Among the subjects receiving cART with an available HIV-RNA measurement at anal sample collection, complete virological suppression was observed in 258 of 297 cases (86.9%). Most of the patients were in stage A (64.4%), whereas 42 (12.4%) in stage C.
The sociodemographic and behavioral characteristics of the study groups are shown in Table 1 . HIV-negative subjects reported a significantly higher number of recent partners (P < .001). HIV-infected individuals less frequently reported having sex with occasional partners (P < .001), whereas they more frequently reported having had an STI (P < .001) and anogenital warts (P 5 .02). The majority of individuals in both groups reported that they practiced receptive anal sex (P 5 .14).
Anal Cytological Lesions
Among the samples collected from the HIV-uninfected and HIV-infected MSM, 89 of 633 (14.1%) and 33 of 388 (8.5%), respectively, were inadequate for morphological evaluation because of low cellularity (9 of Table 2 shows the distribution of the cytological reports for the adequate specimens according to HIV status. Anal cytological lesions (ie, ASCUS1) were observed in 32.5% and 53.2% of the HIV-uninfected and HIVinfected MSM, respectively (P < .0001). LSILs were twice as common among HIV-positive MSM (P < .0001). HSILs were also more frequent in the HIV-infected subjects (4.8% vs 2.7%), although the difference was not statistically significant (P 5 .09). No cases of invasive SCC were found.
The distribution of the cytological lesions according to age class is shown in Figure 1 . In HIV-uninfected MSM, they were more frequent among those 45 years of age (37.3%), whereas in the HIV-infected counterparts, the highest prevalence was observed among those aged 25 to 29 years (66.7%). However, no significant ASCUS 1 -trend across ages was found for either of the 2 study groups (v 2 for HIV-uninfected MSM 5 2.68, P 5 .75; v 2 for HIV-infected MSM 5 4.84, P 5 .44). HSILs were more frequently observed in older HIV-uninfected MSM (7.2% of those aged 45 years), whereas, among HIV-infected individuals, they were more frequent in those aged 35 to 39 years (10.0%). Cancer Cytopathology
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(any type), whereas 95.0% of the HIV-positive individuals harbored an anal HPV infection (P < .0001; Table 3 ). HIV-infected participants significantly differed from the HIV-uninfected counterparts with respect to the frequency of infection with any HR type (77.9% vs 51.5%; P < .0001) and >1 HPV type (79.8% vs 49.1%; P < .0001). The median number of genotypes in multiple infections was also significantly higher in HIV-infected MSM (4; IQR, 2-5) versus HIV-uninfected MSM (2; IQR, 1-3; P < .001; data not shown). HPV-16 was the most prevalent genotype in both populations (17.9% among HIV-negative MSM and 26.8% among HIVpositive MSM; data not shown).
Anal Cytological Lesions and HPV Infection
The frequency of infection with any HR type and HPV-16 and/or HPV-18 (HPV-16/18) by cytological report is shown in Figure 2 . The prevalence of any HR type significantly increased with the grade of the cytological report in both populations ( Fig. 2A ). All the subjects with an HSIL were positive for HR types, except for 1 case found among the HIV-infected MSM, who harbored HPV-53. In both groups, the prevalence of HPV-16/18 significantly increased with the grade of the cytological report (Fig. 2B ).
In particular, 50.0% and 66.7% of the HSILs were positive for HPV-16/18 in HIV-uninfected and HIV-infected MSM, respectively. Possible associations between anal cytological lesions and HPV infection were evaluated (Table 4) . In both populations, MSM infected by any HR type had 3-to more than 4-fold increased odds of having ASCUS 1 and LSIL 1 in comparison with those who did not harbor HR types. Individuals with HPV-16/18 were also 2 to 4 times more likely to have cytological lesions than those who were negative for these genotypes. Both HIV-uninfected and HIV-infected participants infected with HR and LR types showed significantly increased odds of having LSIL 1 in comparison with those with only HR types. Finally, the number of HPV genotypes was significantly associated with having ASCUS 1 for both HIV-negative (OR, 1.16; 95% CI, 1.02-1.33) and HIV-positive MSM (OR, 1.42; 95% CI, 1.25-1.60; data not shown). 
DISCUSSION
In this study, 1021 MSM attending the HIV/STI unit of a dermatological institute underwent anal cancer screening with Pap testing. Among HIV-uninfected subjects, a rather high rate of inadequate samples was observed (14.1%). 
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Because our unit is open-access for HIV-uninfected MSM, they are not necessarily seen by scheduled appointments, and they may undergo anal sampling without having adopted particular precautions. Patient behavior in the 24 hours preceding the collection of the anal sample (eg, the use of lubricants or douching with soapy water) may compromise the quality of the specimen and may thus explain the high proportion of unsatisfactory samples among the HIV-uninfected participants. Anal cytological lesions were significantly more common among HIV-infected individuals than uninfected individuals (53.2% vs 32.5%), and this is consistent with the findings of D'Souza et al. 23 Our findings on HIV-infected MSM, including those regarding the HSIL rate, are consistent with other reports, 10,24-27 but they differ from a recent study on HIV-infected German men (98% of whom were MSM), which found abnormal anal cytology in 75% of the participants.
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Notably, the prevalence of cytological lesions peaked in HIV-uninfected individuals 45 years old, whereas among HIV-infected MSM, it peaked in 25-to 29-year-old subjects. Most importantly, the peak of the HSIL rate in HIV-infected individuals preceded that of HIV-uninfected MSM because it was observed in younger individuals (35-39 vs 45 years). Taken together, these results suggest that MSM with an HIV infection develop anal cytological abnormalities not only more frequently than HIV-negative MSM but also at a younger age (around a decade in advance in the current study). Consistently, the median age at an anal cancer diagnosis is 47.4 years for HIV-infected MSM and 57.8 years for HIV-uninfected MSM, 28 and this suggests that an HPV-HIV co-infection modifies the natural history of anal lesion development. An earlier age at HSIL and anal cancer diagnoses in HIV-infected MSM could also be related to earlier HPV exposure in these individuals. Regarding anal HPV infections, the prevalence that we found is similar to that reported in other studies.
10,24,29-31 HPV-16 appeared to be the most prevalent genotype in both study groups, and this might be explained by the high incidence and long persistence of this genotype in anal infections, as shown by longitudinal studies. [32] [33] [34] As expected, we observed that the prevalence of HR types significantly increased with the severity of and in a cross-sectional study of HIV-infected men recruited in Taiwan. 36 We also found that the detection of HPV-16/18, the most prevalent genotypes in anal cancer, 37 increased with the severity of the cytological lesions in both study groups, and there was a peak in HSILs, which were HPV-16/18-positive in 50% to 67% of the cases. Interestingly, a recent meta-analysis showed that only the prevalence of HPV-16, in comparison with other HR types, increased significantly with the anal lesion grade on cytology in both HIVnegative and HIV-positive individuals. 38 In the latter group, the HPV-16 prevalence increased from 26% in subjects with negative cytology to 51% in those with HSILs. Notably, we observed that individuals with HPV-16/ 18 had significantly increased odds of having ASCUS 1 in comparison with those who did not harbor these genotypes. Recently, significantly higher detection of anal cytological lesions has also been reported in HIV-positive MSM with persistent HPV-16 or HPV-18 infections. 31 These findings suggest that HPV tests restricted to these genotypes might find a possible application in anal cancer screening, although no recommendations currently exist regarding the use of HPV testing, mainly because of the very high prevalence of anal HPV infections in populations at risk for anal cancer. The possible utility of HPV testing is still under investigation. 27, [39] [40] [41] Compared with infections with only HR HPVs, the simultaneous presence of HR and LR types increased the odds of having an LSIL 1 report approximately 3 times in both study populations, and this suggests a role for LR genotypes in the appearance of anal cytological lesions. Having an abnormal anal cytology was also associated with the number of concurrent HPV types. The odds of having an ASCUS 1 report increased by 41% in HIV-infected MSM and by 16% in the HIV-uninfected counterparts with a unit increase in the number of genotypes in the anal sample. Although these findings are consistent with those reported by others, 24, 25, 36, 42 it is still unclear whether multiple infections have a role in the development of anal cancer and its precursors. Interestingly, a recent study 43 showed This study has a few limitations. First, data about HPV infections were not available for the entire study population, so not all the cases were included in the analysis. Second, HSIL cases, though in line with the literature, were not frequent, and this might have limited the possibility of observing significant associations with HPV infections at the HSIL 1 threshold. The strength of the observed associations was probably weakened by the very high prevalence of anal HPV in the study subjects. Because the participants homogeneously reported risky sexual behavior, our findings may not be representative of all urban MSM. Finally, the group of HIV-infected MSM lacked individuals with severe immunosuppression, and this probably hampered the chance of finding possible associations between anal lesions and the level of immunosuppression. However, this study also has several strengths. To the best of our knowledge, this is the largest study that has assessed anal cytological lesions in MSM in Europe. In addition, it provides information regarding both HIVinfected and HIV-uninfected individuals and data on anal HPV infections for almost 800 MSM.
In conclusion, routine anal cytology evidenced a high rate of lesions in MSM, particularly among those with HIV-1 infection. Importantly, cART-receiving patients represented more than three-quarters of our HIV-infected participants, and this indicates that anal lesions are very common even among immunorestored and aviremic HIVinfected patients. Our findings underline not only that vaccination of MSM with the currently available prophylactic HPV vaccines should be promoted but also that additional diagnostic procedures, such as HRA, should be implemented in clinical centers dealing with populations at risk for anal cancer to manage the large proportion of patients with an abnormal Pap test. Triage strategies might be useful for limiting the demand for HRA referrals, which is
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Cancer Cytopathology 468 very high when referrals are based only on cytology. For instance, genotype-restricted tests that identify HPV-16 and/or HPV-18 DNA (or RNA) might be useful for selecting individuals with an ASCUS or LSIL report at higher risk for an underlying HGAIN. Indeed, a recent study 45 has provided further confirmation that grade 2 or higher anal intraepithelial neoplasia/HGAIN may be diagnosed in patients with a report of an LSIL or less. Finally, differences in the prevalence of cytological lesions by age among HIV-infected and HIV-uninfected MSM should be considered in planning anal cancer screening programs tailored for these groups.
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